期刊文献+

S100A12在子痫前期患者母血中的表达及相关性研究

Expression of S100A12 in the maternal blood of patients with pre-eclampsia
原文传递
导出
摘要 目的探讨S100A12在子痫前期患者母血清中的表达和临床意义。方法分别抽取24例子痫前期轻度患者、24例子痫前期重度患者以及24例正常妊娠妇女的血液,收集所有患者完整的病例资料,采用免疫印迹法检测血清中S100A12蛋白表达水平,并采双抗体夹心酶联免疫吸附法检测血清中TNF-α和IL-6的表达。结果与正常组相比,子痫前期患者血清中S100A12、IL-6和TNF-α的表达水平显著升高(P<0.05),且S100A12的表达水平与IL-6存在显著正相关性(P<0.05)。结论 S100A12在子痫前期患者血清中的表达水平明显升高,有可能用于临床上子痫患者的诊断和治疗。 Objective:To explore the relationship of S100A12 in the maternal blood of patients with pre-eclampsia and their roles on pathogenesis of pre-eclampsia.Methods:Western blot was used to investigate the expression level of S100A12 in the maternal blood of patients with pre-eclampsia including mild and moderate preeclampsia 24 cases,severe preeclampsia 24 cases and 24 cases normal pregnant women. Maternal and umbilical serum IL-6and TNF-alpha were calculated by using enzyme-linked immunosorbent assay.Results:Compared with the control group,the level of S100A12 protein in maternal blood of pre-eclampsia patients were significantly increased(P〈0.05). Significantly increased maternal and umbilical serum levels of IL-6 and TNFalpha were found in patientswith pre-eclampsia group in comparison with the control group(P〈0.05).There is a significant positive correlation between high expression of IL-6,TNF-α and S100A12 in pre-eclampsia(P〈0.05).Conclusion:S100A12 plays an important role in the pathogenesis of pre-eclampsia and may be served as a therapeutic target for the treatment of pre-eclampsia.
出处 《中国优生与遗传杂志》 2014年第11期95-97,共3页 Chinese Journal of Birth Health & Heredity
关键词 子痫前期 S100A12 Pre-eclampsia S100A12
  • 相关文献

参考文献10

  • 1Ahmed R, Dunford J, Mehran R, et al. Pre-Eclampsia and Future Cardiovascular Risk Among Women :A Review[J]. J Am Coil Cardiol, 2014, 63 (18) : 1815-1822.
  • 2Schramm AM, Clowse ME. Aspirin for Prevention of Preeclampsia in Lupus Pregnancy[J]. Autoimmune Dis, 2014,2014:920467.
  • 3van de Logt F, Day AS. S100A12 :a noninvasive marker ofinflammation in inflammatory bowel disease[J]. J Dig Dis, 2013,14 (2) :62-67.
  • 4Kaiser T, Langhorst J, Wittkowski H, et al. Faecal S100A12 as a non-invasive marker distinguishing inflammatory bowel disease from irritable bowel syndrome[J]. Gut, 2007,56 (12) :1706-1713.
  • 5Foell D, Ichida F, Vogl T, et al. $100A12 (EN-RAGE) in monitoring Kawasaki disease[J]. Lancet, 2003,361 (9365) : 1270-1272.
  • 6Baillet A, Trocme C, Berthier S, et al. Synovial fluid proteomic fingerprint :$100A8, $100A9 and $100A12 proteins discriminate rheumatoid arthritis from other inflammatory joint diseases[J]. Rheumatology (Oxford),2010,49 (4) :671-682.
  • 7Dabritz J, Langhorst J, Lugering A, et al. Improving relapse prediction in inflammatory bowel disease by neutrophil-derived S100A12[J]. Inflamm Bowel Dis,2013,19 (6) :1130-1138.
  • 8Heilmann RM, GreUet A, Allenspach K, et al. Association between fecal $100A12 concentration and histologic, endoscopic, and clinical disease severity in dogs with idiopathic inflammatory bowel disease[J]. Vet Immunol lmmunopathol, 2014,158 (3-4) :156-166.
  • 9Roberts JM, Bell MJ. If we know so much about preeclampsia, why haven't we cured the disease[J]. J Reprod Immunol, 2013,99 ( 1-2): 1-9.
  • 10Lau SY, Guild SJ, Barrett CJ, et al. Tumor necrosis factor- alpha, interleukin-6, and interleukin-10 levels are altered in preeclampsia :a systematic review and meta-analysis[J]. Am J Reprod Immunol, 2013, 70 (5) :412-427.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部